Hennion & Walsh Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Hennion & Walsh Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,764	Closed	-$225K	–	920
2025 Q1	$225K	Sell	7,764 -175	-2%	-$5.59K	0.01%	809
2024 Q4	$295K	Sell	7,939 -93	-1%	-$4.25K	0.01%	763
2024 Q3	$390K	Sell	8,032 -55	-0.7%	-$2.41K	0.02%	678
2024 Q2	$323K	Sell	8,087 -147	-2%	-$6.09K	0.02%	707
2024 Q1	$362K	Sell	8,234 -3,022	-27%	-$156K	0.02%	643
2023 Q4	$696K	Buy	11,256 +2,328	+26%	+$122K	0.04%	486
2023 Q3	$411K	Buy	8,928 +2,050	+30%	+$112K	0.03%	574
2023 Q2	$395K	Sell	6,878 -104	-1%	-$4.61K	0.02%	579
2023 Q1	$262K	Buy	+6,982	New	+$229K	0.02%	680
2022 Q4	–	Sell	-7,286	Closed	-$205K	–	769
2022 Q3	$205K	Buy	+7,286	New	+$238K	0.01%	712

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Hennion & Walsh Asset Management's AMPH Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 7,764 shares — an estimated $225K sold.

Hennion & Walsh Asset Management first reported a position in AMPH in Q3 2022 and held it in 10 quarters. The position peaked at $696K in Q4 2023. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

Hennion & Walsh Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Hennion & Walsh Asset Management sold 7,764 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $225K.
Hennion & Walsh Asset Management first reported a position in Amphastar Pharmaceuticals in Q3 2022 and held it in 10 quarters.
Hennion & Walsh Asset Management's Amphastar Pharmaceuticals position peaked at $696K in Q4 2023.
245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.